New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

Author(s): Rita Assi, Sally Temraz, Ali Shamseddine and Deborah Mukherji

Volume 17, Issue 3, 2016

Page: [290 - 302] Pages: 13

DOI: 10.2174/1389450116666150907101044

Price: $65


The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.

Keywords: Prostate cancer, androgen receptor, abiraterone, enzalutamide.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy